Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Eric G. Carter"'
Autor:
Robert T. Lyons, Eric G. Carter
Publikováno v:
Lipid Technologies and Applications
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::45493a4dc2e116501ee17037762ab29c
https://doi.org/10.1201/9780203748848-21
https://doi.org/10.1201/9780203748848-21
Autor:
George E. Dukes, Emeran A. Mayer, Eric G. Carter, David J. McSorley, Vanessa Z. Ameen, Lin Chang
Publikováno v:
The American Journal of Gastroenterology. 100:115-123
A randomized, double blind, placebo-controlled dose-ranging study was conducted to assess the efficacy of alosetron in men with diarrhea-predominant irritable bowel syndrome (IBS).Six hundred and sixty-two men were randomized to treatment with aloset
Autor:
Northcutt Allison Ruth, Vanessa Z Ameen, Amy T Heath, William Y. Chey, George E. Dukes, William D. Chey, Eric G. Carter
Publikováno v:
The American Journal of Gastroenterology. 99:2195-2203
To assess long-term safety and efficacy of alosetron in women with severe, chronic diarrhea-predominant IBS and in a subset having more frequent urgency (i.e., bowel urgency at least 10 of 14 days during screening).Randomized patients received either
Publikováno v:
Gastroenterology Nursing. 25:192-200
The effective management of irritable bowel syndrome (IBS) is enhanced by a therapeutic relationship between healthcare providers and the patient. This survey focused on addressing the symptoms and impact of IBS in women, as well as physician percept
Publikováno v:
Gastroenterology Nursing. 24:281-287
Nurses in a variety of clinical settings are often involved in educating and managing patients with irritable bowel syndrome, though their knowledge and perceptions of irritable bowel syndrome are not well known. A national survey was undertaken as a
Autor:
Priti Jhingran, Tony Lembo, Eric G. Carter, Barbara Bagby, C Decker, Susan Gordon, Richard A. Wright
Publikováno v:
The American Journal of Gastroenterology. 96:2662-2670
Bowel urgency is one of the most bothersome symptoms for nonconstipated IBS patients. The efficacy of alosetron in control of bowel urgency and Global Improvement of IBS symptoms were evaluated in a multicenter double-blind, randomized, placebo-contr
Autor:
Ravindra Murthy, Franchesca Robichaud, Jennifer Phemister, Mark Young, Pranav Patel, Aaysha Kapila, Eric G. Carter
Publikováno v:
American Journal of Gastroenterology. 109:S219-S220
Autor:
Pranav Patel, Ravindra Murthy, Eric G. Carter, Atif Saleem, Aaysha Kapila, Jason McKinney, Mark Young, Jennifer Phemister
Publikováno v:
American Journal of Gastroenterology. 109:S98-S99
Autor:
Marquita A. West, Amy T Heath, Vanessa Z. Ameen, Richard Krause, Susan H. Gordon, Eric G. Carter, T. Perschy
Publikováno v:
The American journal of gastroenterology. 102(8)
Alosetron is indicated for women with chronic, severe diarrhea-predominant IBS (d-IBS) who have not responded adequately to conventional therapy. Constipation is the most common adverse event with alosetron treatment. Multiple dosing regimens were as
Autor:
E. Mortensen, Jan Peter Jansen, Gordon Irving, Lynn R. Webster, Ben Lasko, John F. Peppin, Bart Morlion, Amy Pierce, Jerry Snidow, Christi S. Kleoudis, Eric G. Carter
Publikováno v:
PainReferences. 137(2)
Our objective was to investigate the efficacy and safety of alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist, in subjects with non-cancer pain and opioid-induced bowel dysfunction (OBD), and to identify at least one treatment r